GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine, where concentrations decline substantially with age. It promotes tissue remodeling by upregulating matrix metalloproteinases (MMP-2, MMP-9), stimulating collagen and glycosaminoglycan synthesis, and modulating TGF-β signaling, with additional roles in angiogenesis and anti-inflammatory gene expression. The best-documented human evidence is topical: randomized controlled trials show improvements in skin elasticity, wrinkle depth, and photoaging with GHK-Cu containing formulations. Systemic injectable evidence is limited to preclinical models; extrapolating topical skin data to injected systemic outcomes is not supported by current human research.
Evidence last reviewed: 15 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Verify this peptide on CertiPep
certipep.ch — anonymous purity & characterization service
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence for GHK-Cu primarily comes from topical applications, showing some improvements in skin metrics. However, the strength of the evidence is low to moderate, with significant gaps in understanding its systemic effects.
Extracellular matrix remodeling via MMP-2 upregulationIn vitro (human fibroblast cultures) · In vitro mechanistic studyLow
GHK-Cu significantly increased MMP-2 (matrix metalloproteinase-2) protein levels and corresponding mRNA in fibroblast culture media. TIMP-1 and TIMP-2 secretion also rose, indicating balanced matrix remodeling activity. The copper component was essential - GHK peptide alone produced no effect. Authors conclude GHK-Cu acts as both an activator of connective tissue production and a regulator of extracellular matrix remodeling.
Wrinkle improvement (objective measures)Adults using topical copper tripeptide complex · Clinical study (objective evaluation)Low
One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations & endpoints.
Skin appearance / remodeling (summary of clinical + mechanistic evidence)Humans (cosmetic/dermatologic contexts) + preclinical · ReviewModerate
Review summarizes reported improvements in some skin measures & broad tissue-remodeling biology; quality & comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.
Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.
BPC-157 & TB-500 are the two most researched recovery peptides, with complementary mechanisms. BPC-157 (Body Protection Compound) accelerates tendon, ligament, & gut repair via angiogenesis & growth factor upregulation. TB-500 (Thymosin Beta-4) promotes systemic tissue repair, reduces inflammation, & improves mobility. GHK-Cu supports collagen synthesis & skin regeneration. Note: all three are research compounds not approved for human therapeutic use.
KLOW Stack
The KLOW stack is a 4-peptide protocol targeting systemic inflammation, tissue repair, and cellular regeneration. It combines BPC-157 (gut and musculoskeletal healing), TB-500 (vascularisation and muscle/tendon recovery), KPV (anti-inflammatory gut protection), and GHK-Cu (collagen remodelling and skin/hair health). It is designed as an evolution of the GLOW stack with a stronger anti-inflammatory focus and broader systemic repair coverage.